Russell Weiner

Biopharmaceutical executive with 30+ years of leadership in oncology, immuno-oncology, rare diseases, and biologics drug development across Merck, Bristol-Myers Squibb, Daiichi Sankyo, Takeda, the Bill & Melinda Gates Medical Research Institute, and Alexion Pharmaceuticals (AstraZeneca Rare Disease).Led global translational sciences, biomarker, precision medicine, and companion diagnostics (CDx) organizations driving discovery-to-registration success across diverse modalities and therapeutic areas.Contributed to the development and approval of Keytruda® and its associated CDx, Yervoy®, Erbitux®, Enhertu®, and Nulojix®. Built and scaled global organizations integrating translational medicine, biomarker discovery, regulated bioanalysis, clinical operations, and human biorepositories, supporting 30+ INDs and global development programs.Extensive global leadership experience across North America, Europe, and Asia, including work with teams, laboratories, and clinical programs in Singapore, Japan, India, China, and South Africa.Recognized for combining deep scientific expertise with strategic leadership to advance precision medicine and biomarker-driven development. Experienced in translating complex biology into executable clinical strategies and decision-enabling data.Currently serve as Immediate Past President and Board Member of the American Association of Pharmaceutical Scientists (AAPS) and on the BioIVT Scientific Advisory Board (former Chair). Passionate about building high-performing teams and enabling the successful translation of science into impactful therapies for patients.